← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

ALBT logoAvalon GloboCare Corp.(ALBT)Earnings, Financials & Key Ratios

ALBT•NASDAQ•REIT / Real Estate
$0.41
$387758 mkt cap·Price updated May 6, 2026
SectorReal EstateIndustryReal Estate ServicesSub-IndustryReal estate owners and developers
AboutAvalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Show more
  • Revenue$1M+6.2%
  • FFO-$8M+53.6%
  • FFO/Share-8.12-421.9%
  • FFO Payout0%
  • FFO per Share-8.12-421.9%
  • NOI Margin20.09%+5.9%
  • FFO Margin-570.19%+56.3%
  • ROE-109.23%+39.4%
  • ROA-38.03%+54.1%
  • Debt/Assets37.36%-10.9%
  • Book Value/Share7.58+983.5%
Technical→

ALBT Key Insights

Avalon GloboCare Corp. (ALBT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 7/9
  • ✓Share count reduced 91.1% through buybacks
  • ✓Trading at only 0.1x book value

✗Weaknesses

  • ✗FFO declining 29.3% TTM
  • ✗Weak momentum: RS Rating 2 (bottom 2%)
  • ✗Low NOI margin of 20.1%
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ALBT Price & Volume

Avalon GloboCare Corp. (ALBT) stock price & volume — 10-year historical chart

Loading chart...

ALBT Growth Metrics

Avalon GloboCare Corp. (ALBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-2.92%
3 Years-1.4%
TTM6.66%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-28.41%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-220.21%

Return on Capital

10 Years-95.89%
5 Years-104.65%
3 Years-77.35%
Last Year-47.1%

ALBT Peer Comparison

Avalon GloboCare Corp. (ALBT) competitors in Real estate owners and developers — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
CELC logoCELCCelcuity Inc.Direct Competitor6.03B139.44-49.27-179%0.85
NKTR logoNKTRNektar TherapeuticsDirect Competitor1.67B85.09-8.75-43.89%-192.87%-356.81%0.95
SNGX logoSNGXSoligenix, Inc.Direct Competitor3.34M0.33-0.07-267.1%0.36
FATE logoFATEFate Therapeutics, Inc.Product Competitor264.17M2.29-1.99-51.24%-20.51%-65.79%0.38
CRSP logoCRSPCRISPR Therapeutics AGProduct Competitor5.31B55.08-8.51-89.97%-138.57%-30.88%0.21
NTLA logoNTLAIntellia Therapeutics, Inc.Product Competitor1.61B13.85-3.64-100%-61.47%0.14
BEAM logoBEAMBeam Therapeutics Inc.Product Competitor3.32B32.33-39.92120.01%-57.24%-7.31%0.24
EDIT logoEDITEditas Medicine, Inc.Product Competitor310.73M3.18-1.76-100%-5.23%0.66

Compare ALBT vs Peers

Avalon GloboCare Corp. (ALBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CELC

Most directly comparable listed peer for ALBT.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ALBT against a more recognizable public peer.

Peer Set

Compare Top 5

vs CELC, NKTR, SNGX, FATE

ALBT Income Statement

Avalon GloboCare Corp. (ALBT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Revenue616.45K1.08M1.56M1.55M1.38M1.39M1.2M1.26M1.33M1.4M
Revenue Growth %-74.8%44.98%-1.02%-10.9%0.96%-13.57%4.45%6.19%6.66%
Property Operating Expenses73.07K829.79K1.17M1.21M987.56K976.45K929.44K1.02M1.07M1.04M
Net Operating Income (NOI)
543.38K▲ 0%
247.76K▼ 54.4%
388.01K▲ 56.6%
339.91K▼ 12.4%
390.2K▲ 14.8%
414.52K▲ 6.2%
272.73K▼ 34.2%
238.19K▼ 12.7%
267.83K▲ 12.4%
358.81K▲ 0%
NOI Margin %88.15%22.99%24.84%21.98%28.32%29.8%22.69%18.97%20.09%25.7%
Operating Expenses466.45K2.78M7.96M19.72M12.84M9.25M9.07M15.99M5.2M7.44M
G&A Expenses466.45K2.8M8.02M16.93M11.96M8.22M6.98M7.31M4.35M6.01M
EBITDA76.96K-3.7M-7.11M-18.87M-12.08M-8.4M-8.33M-15.42M-4.63M-6.82M
EBITDA Margin %12.48%-343.02%-454.99%-1220.36%-876.46%-603.54%-692.63%-1228.32%-347.03%-488.73%
Depreciation & Amortization26181.64K522.84K506.74K378.48K438.78K466.28K329.95K300.47K258.23K
D&A / Revenue %0%16.86%33.47%32.77%27.47%31.54%38.79%26.28%22.53%18.5%
Operating Income
76.93K▲ 0%
-3.88M▼ 5140.6%
-7.63M▼ 96.8%
-19.38M▼ 153.9%
-12.45M▲ 35.7%
-8.83M▲ 29.1%
-8.79M▲ 0.5%
-15.75M▼ 79.2%
-4.93M▲ 68.7%
-7.08M▲ 0%
Operating Margin %12.48%-359.88%-488.46%-1253.13%-903.93%-635.08%-731.42%-1254.59%-369.56%-507.23%
Interest Expense0138.11K314.65K608.33K168.76K200.48K3.58M1.35M2.44M2.15M
Interest Coverage--28.08x-24.25x-31.85x-73.80x-44.06x-2.46x-11.66x-2.02x-
Non-Operating Income-57533.67K53.53K-1.39M56.66K56.19K-438.38K-398.18K538.69K9.63M
Pretax Income
77.51K▲ 0%
-4.05M▼ 5324.8%
-8.05M▼ 98.8%
-18.07M▼ 124.4%
-12.68M▲ 29.8%
-9.09M▲ 28.3%
-11.93M▼ 31.2%
-16.71M▼ 40.0%
-7.9M▲ 52.7%
-18.92M▲ 0%
Pretax Margin %12.57%-375.82%-515.42%-1168.6%-920.29%-653.54%-992.44%-1330.51%-592.72%-1355.2%
Income Tax21.93K000000000
Effective Tax Rate %28.29%0%0%0%0%0%0%0%0%0%
Net Income
55.58K▲ 0%
-3.46M▼ 6332.9%
-7.77M▼ 124.4%
-18.07M▼ 132.4%
-12.68M▲ 29.8%
-9.09M▲ 28.3%
-11.93M▼ 31.2%
-16.71M▼ 40.0%
-7.9M▲ 52.7%
-18.92M▲ 0%
Net Margin %9.02%-321.5%-497.61%-1168.6%-920.29%-653.54%-992.44%-1330.51%-592.72%-1355.2%
Net Income Growth %279.26%-6332.86%-124.41%-132.44%29.83%28.31%-31.25%-40.03%52.69%-28.41%
Funds From Operations (FFO)
55.61K▲ 0%
-3.28M▼ 6003.3%
-7.25M▼ 120.9%
-17.56M▼ 142.2%
-12.3M▲ 30.0%
-8.65M▲ 29.7%
-11.46M▼ 32.5%
-16.38M▼ 42.8%
-7.6M▲ 53.6%
-18.66M▲ 0%
FFO Margin %9.02%-304.64%-464.15%-1135.83%-892.82%-621.99%-953.66%-1304.24%-570.19%-1336.71%
FFO Growth %-61.52%-6003.3%-120.9%-142.21%29.96%29.67%-32.51%-42.85%53.58%-478.33%
FFO per Share0.01-0.50-1.01-2.34-1.55-1.02-1.23-1.56-8.12-4.59
FFO Payout Ratio %0%0%0%0%0%0%0%0%0%0%
EPS (Diluted)
0.01▲ 0%
-0.53▼ 4962.4%
-1.08▼ 103.8%
-2.41▼ 123.1%
-1.61▲ 33.2%
-1.09▲ 32.3%
-1.36▼ 24.8%
-1.59▼ 16.9%
-8.44▼ 430.8%
-4.65▲ 0%
EPS Growth %106.06%-4962.39%-103.77%-123.15%33.2%32.3%-24.77%-16.91%-430.82%-220.21%
EPS (Basic)0.01-0.53-1.08-2.41-1.61-1.09-1.36-1.59-8.44-
Diluted Shares Outstanding5.11M6.5M7.2M7.51M7.95M8.49M9.33M10.53M936.61K4.07M

ALBT Balance Sheet

Avalon GloboCare Corp. (ALBT) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Total Assets3.71M12.67M13.4M10.49M10.37M10.24M19.75M20.58M20.99M9.13M
Asset Growth %1910471.13%241.81%5.74%-21.69%-1.18%-1.2%92.85%4.21%1.96%-158.24%
Real Estate & Other Assets025.32K7.88M7.83M7.94M374.76K16.74M7.47M7.09M102.16K
PP&E (Net)29548.03K249.56K601.42K616.45K506.85K149.18K166.33K17.62K89.84K
Investment Securities01000K385.16K483.1K521.76K1000K485.01K1000K1000K1000K
Total Current Assets3.71M3.23M3.63M1.57M1.29M1.15M2.37M850.87K3.24M2M
Cash & Equivalents2.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K2.86M333.93K
Receivables70.23K48.65K52.22K243.89K35.4K90.87K134.63K234.66K122.96K1000K
Other Current Assets49.8K42.46K127.26K562.32K31.11K18.31K247.99K270.55K103.94K58.94K
Intangible Assets01.58M1.26M0000000
Total Liabilities160.32K5.36M2.14M6.03M6.25M7.16M8.59M13.21M13.88M13.62M
Total Debt01.5M1M3.19M3.73M3.3M4.57M8.64M7.84M7.25M
Net Debt-2.89M-1.53M-1.25M2.43M3.01M2.49M2.58M8.35M4.98M6.91M
Long-Term Debt001M3.19M3.59M2.75M4.56M6.45M00
Short-Term Borrowings01.5M000541.4K02.05M7.83M7.16M
Capital Lease Obligations0000143.33K5.9K11.44K134.25K10.71K324.05K
Total Current Liabilities160.32K5.36M1.14M2.84M2.59M4.4M3.58M6.76M13.88M13.6M
Accounts Payable70.23K296.7K84.32K87.19K00000
Deferred Revenue012.77K28.96K023.51K8.64K27.68K11.43K38.35K0
Other Liabilities000000450K000
Total Equity
3.55M▲ 0%
7.31M▲ 106.1%
11.25M▲ 54.0%
4.47M▼ 60.3%
4.12M▼ 7.8%
3.08M▼ 25.1%
11.16M▲ 261.8%
7.37M▼ 34.0%
7.1M▼ 3.6%
-4.49M▲ 0%
Equity Growth %65697.32%106.1%53.98%-60.32%-7.8%-25.08%261.79%-33.97%-3.61%-612.09%
Shareholders Equity3.55M7.89M12.12M4.47M4.12M3.08M11.16M7.37M7.1M-4.49M
Minority Interest0-585.39K-862.2K0000000
Common Stock6.16K7.03K7.38K7.67K8.28K8.9K1K1.1K145410
Additional Paid-in Capital3.68M11.49M24.15M34.59M46.86M54.89M65.95M67.89M72.02M87.49M
Retained Earnings-53.37K-3.52M-11.29M-29.36M-42.04M-51.13M-63.06M-79.77M-87.67M-103.87M
Preferred Stock0000009M20M23.5M12.63M
Return on Assets (ROA)3%-42.31%-59.65%-151.3%-121.59%-88.22%-79.55%-82.84%-38.03%-207.26%
Return on Equity (ROE)3.14%-63.83%-83.76%-229.91%-295.49%-252.47%-167.53%-180.35%-109.23%901.59%
Debt / Assets-11.84%7.47%30.41%36.01%32.2%23.16%41.95%37.36%79.39%
Debt / Equity-0.21x0.09x0.71x0.91x1.07x0.41x1.17x1.10x1.10x
Net Debt / EBITDA-37.50x---------1.01x
Book Value per Share0.691.121.560.590.520.361.200.707.58-1.10

ALBT Cash Flow Statement

Avalon GloboCare Corp. (ALBT) cash flow — operating, investing & free cash flow history

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Cash from Operations13.98K-1.34M-4.4M-7.08M-7.55M-5.02M-7.04M-6.5M-4.97M-4.97M
Operating CF Growth %146.45%-9680.18%-228.14%-61.05%-6.59%33.42%-40.06%7.57%23.61%-140.55%
Operating CF / Revenue %2.27%-124.33%-281.38%-457.86%-547.71%-361.22%-585.38%-518.02%-372.67%-355.94%
Net Income55.58K-4.05M-8.05M-18.07M-12.68M-9.09M-11.93M-16.71M-7.9M-18.92M
Depreciation & Amortization26181.64K522.84K506.74K378.48K438.78K466.28K329.95K300.47K258.23K
Stock-Based Compensation52.55K993K3.09M9.21M5.49M2.11M1.11M1.18M521.51K687.65K
Other Non-Cash Items52.55K1.32M52.97K1.39M7.55K17.31K3.11M8.73M3.34M11.69M
Working Capital Changes-94.17K213.98K-12.51K1.64M-856.21K1.5M206.89K-35.07K-1.23M783.8K
Cash from Investing-930.33K-8.01M-1.31M-552.97K-169.19K-68.14K-9.05M-22.16K-100K791.01K
Acquisitions (Net)-230K72.03K-803.16K-159.19K-57.97K-40.3K-52K0-100K133.3K
Purchase of Investments0-7.01M-844.66K-175.51K-169.19K0-9.05M000
Sale of Investments000175.51K001000K00743.96K
Other Investing-700K-7.16M-391.51K-16.32K57.97K-10.33K-9M00-86.24K
Cash from Financing3.79M9.5M5.04M6.15M7.66M5.17M17.26M4.83M7.64M4.01M
Dividends Paid0000000000
Common Dividends0000000000
Debt Issuance (Net)01000K-500K1000K400K1000K1000K1000K-420.47K-174.77K
Share Repurchases00-522.5K0000000
Other Financing150K2.85M-1.49M00-240.43K-290.52K74.95K1.7M71.01K
Net Change in Cash
2.78M▲ 0%
140.84K▼ 94.9%
-774.75K▼ 650.1%
-1.49M▼ 92.0%
-38.31K▲ 97.4%
80.96K▲ 311.3%
1.18M▲ 1361.7%
-1.71M▼ 244.1%
2.57M▲ 250.7%
-690.27K▲ 0%
Exchange Rate Effect-92.05K-7.24K-113.13K-9.47K12.69K3.44K10.08K-3.97K1.45K9.49K
Cash at Beginning109.59K2.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K201.53K
Cash at End2.89M3.03M2.25M764.89K726.58K807.54K1.99M285.4K2.86M333.93K
Free Cash Flow
13.65K▲ 0%
-2.27M▼ 16727.0%
-4.51M▼ 98.7%
-7.46M▼ 65.4%
-7.55M▼ 1.2%
-5.04M▲ 33.2%
-7.04M▼ 39.6%
-6.53M▲ 7.3%
-4.97M▲ 23.9%
-5.5M▲ 0%
FCF Growth %145.34%-16727.04%-98.68%-65.38%-1.19%33.18%-39.61%7.28%23.87%-25.35%
FCF / Revenue %2.21%-210.63%-288.63%-482.27%-547.71%-362.48%-585.52%-519.79%-372.67%-393.67%

ALBT Key Ratios

Avalon GloboCare Corp. (ALBT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201620172018201920202021202220232024TTM
FFO per Share0.01-0.5-1.01-2.34-1.55-1.02-1.23-1.56-8.12-4.59
FFO Payout Ratio0%0%0%0%0%0%0%0%0%0%
NOI Margin88.15%22.99%24.84%21.98%28.32%29.8%22.69%18.97%20.09%25.7%
Net Debt / EBITDA-37.50x---------1.01x
Debt / Assets-11.84%7.47%30.41%36.01%32.2%23.16%41.95%37.36%79.39%
Interest Coverage--28.08x-24.25x-31.85x-73.80x-44.06x-2.46x-11.66x-2.02x-
Book Value / Share0.691.121.560.590.520.361.20.77.58-1.1
Revenue Growth-74.8%44.98%-1.02%-10.9%0.96%-13.57%4.45%6.19%6.66%

ALBT Frequently Asked Questions

Avalon GloboCare Corp. (ALBT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Avalon GloboCare Corp. (ALBT) reported $1.4M in revenue for fiscal year 2024.

Avalon GloboCare Corp. (ALBT) grew revenue by 6.2% over the past year. This is steady growth.

Avalon GloboCare Corp. (ALBT) reported a net loss of $18.9M for fiscal year 2024.

Dividend & Returns

Avalon GloboCare Corp. (ALBT) has a return on equity (ROE) of -109.2%. Negative ROE indicates the company is unprofitable.

Industry Metrics

Avalon GloboCare Corp. (ALBT) generated Funds From Operations (FFO) of $-18.7M in the trailing twelve months. FFO is the primary profitability metric for REITs.

Explore More ALBT

Avalon GloboCare Corp. (ALBT) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.